HIV Mutation Detail Information

> M184V Search Result

Mutation Information

Mutation Site	M184V
Mutation Type	Amino acid level
Gene/Protein/Region Type	RT
Relevant Drug	lamivudine (LAM)
Country	UK

Literature Information

PubMed PMID	31927793
Disease	HIV infection/AIDS
Published Year	2020
Journal	HIV medicine
Title	Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.
Author	Stirrup OT,Asboe D,Pozniak A,Sabin CA,Gilson R,Mackie NE,Tostevin A,Hill T,Dunn DT,UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort.
Evidence	Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutationThe aim of the study was to investigate whether lamivudine (3TC) or emtricitabine (FTC) use following detection of M184V/I is associated with better virological outcomes.

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation